Compounds > etravirine
Page last updated: 2024-09-05

etravirine and rilpivirine

etravirine has been researched along with rilpivirine in 71 studies

Compound Research Comparison

Studies
(etravirine)		Trials
(etravirine)		Recent Studies (post-2010)
(etravirine)		Studies
(rilpivirine)		Trials
(rilpivirine)		Recent Studies (post-2010) (rilpivirine)
5729032158093513

Protein Interaction Comparison

ProteinTaxonomyetravirine (IC50)rilpivirine (IC50)
Gag-Pol polyproteinHIV-1 M:B_HXB2R0.068
Cytochrome P450 1A2Homo sapiens (human)6.1612
Cytochrome P450 3A4Homo sapiens (human)1.7406
Cytochrome P450 2D6Homo sapiens (human)2.3635
Cytochrome P450 2C9 Homo sapiens (human)0.2818
Cytochrome P450 2C19Homo sapiens (human)0.3363
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)0.5
Reverse transcriptase/RNaseH Human immunodeficiency virus 10.0759
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)1.5

Research

Studies (71)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (7.04)29.6817
2010's52 (73.24)24.3611
2020's14 (19.72)2.80

Authors

AuthorsStudies
Arnold, E; Clark, AD; Das, K; Frenkel, YV; Janssen, PA; Lewi, PJ; Wang, YH1
Chen, CH; Jiang, S; Lai, W; Lee, KH; Lu, H; Qin, B; Tian, X; Xie, L1
Grimberg, BT; Hough, LB; Jaworska, MM; Phillips, JG; Zimmerman, PA1
Azijn, H; Boven, K; de Béthune, MP; Jochmans, D; Kraus, G; Picchio, G; Rimsky, LT; Tirry, I; Van Craenenbroeck, E; Vingerhoets, J1
Anderson, KS; Bollini, M; Domaoal, RA; Gallardo-Macias, R; Jorgensen, WL; Spasov, KA; Thakur, VV1
De Clercq, E; Li, D; Liu, X; Zhan, P1
Chen, CH; Huang, L; Lee, KH; Qian, K; Qin, B; Sun, LQ; Xie, L; Zhu, L1
Chong, P; Edelstein, M; Ferris, RG; Garrido, D; Mathis, A; Nolte, RT; Peat, A; Sebahar, P; Stewart, EL; Wang, L; Weaver, K; Youngman, M; Zhang, H1
Anderson, KS; Bollini, M; Gallardo-Macias, R; Jorgensen, WL; Spasov, KA; Tirado-Rives, J1
Chen, FE; Daelemans, D; De Clercq, E; Liu, Y; Ma, XD; Pannecouque, C; Yang, S1
Anderson, KS; Bollini, M; Cisneros, JA; Jorgensen, WL; Spasov, KA1
Asante-Appiah, E; Bayly, C; Bédard, L; Blouin, M; Burch, JD; Campeau, LC; Cauchon, E; Chan, M; Chefson, A; Côté, B; Coulombe, N; Cromlish, W; Debnath, S; Deschênes, D; Ducharme, Y; Dupont-Gaudet, K; Falgueyret, JP; Forget, R; Gagné, S; Gauvreau, D; Girardin, M; Guiral, S; Langlois, E; Li, CS; Nguyen, N; Ouellet, S; Papp, R; Plamondon, S; Roy, A; Roy, S; Seliniotakis, R; St-Onge, M; Tawa, P; Truchon, JF; Vacca, J; Wrona, M; Yan, Y1
Balzarini, J; Chen, W; De Clercq, E; Liu, H; Liu, X; Pannecouque, C; Rai, D; Zhan, P; Zhou, Z1
Anderson, KS; Bollini, M; Frey, KM; Gallardo-Macias, R; Jorgensen, WL; Lee, WG; Spasov, KA1
Elgaher, WA; Hartmann, RW; Haupenthal, J; Mély, Y; Pires, M; Real, E; Saladini, F; Sharma, KK1
Jorgensen, WL1
Chen, CH; Huang, L; Lee, KH; Morris-Natschke, SL; Wang, HL; Wei, L; Xie, L1
Chen, CH; Daelemans, D; De Clercq, E; Huang, B; Kang, D; Lee, KH; Liu, J; Liu, X; Liu, Z; Pannecouque, C; Tian, Y; Zhan, P; Zhang, H1
Byrareddy, SN; Kongsted, J; Kramer, VG; Kurup, S; Liu, X; Namasivayam, V; Vanangamudi, M; Zhan, P1
Daelemans, D; De Clercq, E; Kang, D; Liu, X; Pannecouque, C; Tian, Y; Wang, Z; Yu, Z; Zhan, P; Zhang, J1
Anderson, KS; Frey, KM; Gannam, ZTK; Jorgensen, WL; Kudalkar, SN; Lee, WG; Sasaki, T; Spasov, KA1
Arnold, E; De Clercq, E; Fang, Z; Feng, D; Kang, D; Liu, X; Pannecouque, C; Pilch, A; Ruiz, FX; Sun, Y; Wang, Z; Wei, F; Zhan, P; Zhao, T1
De Clercq, E; Frutos-Beltrán, E; Gao, P; Kang, D; Li, W; Liu, X; Menéndez-Arias, L; Pannecouque, C; Song, S; Sun, B; Zhan, P; Zhang, J; Zou, J1
Arnold, E; De Clercq, E; Feng, D; Gao, S; Jing, L; Kang, D; Liu, X; Pannecouque, C; Ruiz, FX; Sun, L; Sun, Y; Wang, Z; Zhan, P; Zhang, T1
Chen, FE; De Clercq, E; Ding, L; Pannecouque, C; Zhuang, C3
Daelemans, D; De Clercq, E; Gao, P; Ginex, T; Huang, B; Jiang, X; Kang, D; Liu, X; Luque, FJ; Pannecouque, C; Zhan, P; Zhang, J1
Baidya, ATK; Das, B; Kumar, R; Mathew, AT; Yadav, AK1
Cherukupalli, S; De Clercq, E; Jia, R; Jiang, X; Kang, D; Liu, X; Pannecouque, C; Wang, W; Wang, Z; Xie, M; Zhan, P1
Chen, FE; De Clercq, E; Huang, WJ; Jin, X; Pannecouque, C; Wang, S; Zhang, YX; Zhao, LM1
Chen, FE; Clercq, E; Hao, QQ; Ling, X; Pannecouque, C1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Boone, LR1
Fulco, PP; McNicholl, IR1
Crauwels, HM; Kakuda, TN1
Back, D; Else, L; Hughes, A; Khoo, S; Siccardi, M; Tjia, J; Watson, V1
Birkus, G; Brendza, KM; Hung, M; Jin, D; Kutty, N; Lansdon, EB; Liu, X; Mukund, S; Wang, R1
Coluccia, A; La Regina, G; Silvestri, R1
Tian, XT; Xie, L1
Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S1
Giaquinto, C; Penazzato, M1
Balamane, M; Fessel, WJ; Katzenstein, DA; Melikian, GL; Shafer, RW; Varghese, V1
Calvez, V; Flandre, P; Fofana, DB; Fourati, S; Katlama, C; Lambert, S; Malet, I; Marcelin, AG; Sayon, S; Simon, A; Soulie, C; Wirden, M1
Dilanchian, P; Jayaweera, D1
Asahchop, EL; Brenner, BG; Ibanescu, IR; Moisi, D; Oliveira, M; Tremblay, C; Wainberg, MA; Xu, H1
Lacombe, K; Surgers, L1
Chang, TK; Lau, AJ; Sharma, D; Sherman, MA2
Asahchop, EL; Colby-Germinario, SP; Han, Y; McCallum, M; Oliveira, M; Quan, Y; Sarafianos, SG; Schader, SM; Wainberg, MA; Xu, HT1
Calvez, V; Fofana, DB; Fourati, S; Lambert-Niclot, S; Maiga, AI; Malet, I; Marcelin, AG; Soulie, C; Tounkara, A; Traore, HA; Wirden, M1
Colby-Germinario, SP; Han, Y; Huang, W; Oliveira, M; Petropoulos, CJ; Quan, Y; Wainberg, MA; Xu, HT1
Colby-Germinario, SP; Han, Y; Oliveira, M; Quan, Y; Wainberg, MA; Xu, HT; Zanichelli, V1
Haddad, M; Napolitano, LA; Picchio, GR; Rimsky, LT; Van Eygen, V; Vingerhoets, J1
Crawford, KW1
Aboulker, JP; Charreau, I; de Castro, N; Delaugerre, C; Gallien, S; Mahjoub, N; Molina, JM; Nere, ML; Simon, F1
Feng, M; Grobler, JA; Hazuda, DJ; Lai, MT; Miller, MD; Wang, D1
Álvarez, M; Andrés, C; Betancor, G; Marcelli, B; Martínez, MA; Menéndez-Arias, L1
Bertelsen, KM; Crauwels, HM; Hoetelmans, RM; Kakuda, TN; Leopold, L; Nijs, S; Stevens, M; Tomaka, F; van Delft, Y; Vandevoorde, A; Witek, J1
Hannongbua, S; Ishii, K; Kato, K; Thammaporn, R; Uchiyama, S; Yagi-Utsumi, M1
Avihingsanon, A; Mekprasan, S; Ohata, PJ; Putcharoen, O; Ruxrungtham, K; Sirivichayakul, S; Teeranaipong, P1
Marzinke, MA; Parsons, TL1
Gomathi, S; Kantor, R; Kausalya, B; Mothi, SN; Pachamuthu, B; Pradeep, A; Saravanan, S; Selvamuthu, P; Sivamalar, S; Smith, DM; Sunil, S1
Diphoko, T; Essex, M; Gaseitsiwe, S; Kasvosve, I; Makhema, J; Marlink, R; Moyo, S; Musonda, R; Novitsky, V; Okatch, H; Wainberg, M1
Agher, R; Calvez, V; Katlama, C; Marcelin, AG; Nguyen, T; Nouchi, A; Sayon, S; Simon, A; Soulie, C; Valantin, MA1
Abraham, OC; Demosthenes, JP; Ghale, BC; Kannangai, R; Ramalingam, VV; Rupali, P; Varghese, GM1
Andreoni, M; Antinori, A; Bagnarelli, P; Borghi, V; Bruzzone, B; Callegaro, AP; De Gennaro, M; Gianotti, N; Maffongelli, G; Maggiolo, F; Saladini, F; Sterrantino, G; Vergori, A; Zaccarelli, M; Zazzi, M1
Dunn, KJ; Kagan, RM; Kaufman, HW; Nettles, RE; Snell, GP1
Baszczyňski, O; Brumshtein, B; Dračínský, M; Janeba, Z; Jansa, P; Kaiser, MM; Lansdon, EB; Lee, YJ; Prener, L; Stepan, G; Yu, H1
Castagna, A; Celesia, BM; Cenderello, G; Corbelli, GM; Ferrara, M; Giammarino, F; Gianotti, N; Maggiolo, F; Martellotta, F; Rusconi, S; Saladini, F; Santoro, MM; Spagnuolo, V; Zazzi, M1

Reviews

9 review(s) available for etravirine and rilpivirine

ArticleYear
Design, synthesis and biological evaluation of novel acetamide-substituted doravirine and its prodrugs as potent HIV-1 NNRTIs.
    Bioorganic & medicinal chemistry, 2019, 02-01, Volume: 27, Issue:3

    Topics: Acetamides; Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Prodrugs; Pyridones; Reverse Transcriptase Inhibitors; Triazoles

2019
Structural modification aimed for improving solubility of lead compounds in early phase drug discovery.
    Bioorganic & medicinal chemistry, 2022, 02-15, Volume: 56

    Topics: Drug Discovery; Hydrogen Bonding; Molecular Structure; Prodrugs; Solubility

2022
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Current opinion in investigational drugs (London, England : 2000), 2006, Volume: 7, Issue:2

    Topics: Animals; Anti-HIV Agents; Azepines; Clinical Trials as Topic; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2006
Etravirine and rilpivirine: nonnucleoside reverse transcriptase inhibitors with activity against human immunodeficiency virus type 1 strains resistant to previous nonnucleoside agents.
    Pharmacotherapy, 2009, Volume: 29, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2009
Looking for an active conformation of the future HIV type-1 non-nucleoside reverse transcriptase inhibitors.
    Antiviral chemistry & chemotherapy, 2010, Aug-11, Volume: 20, Issue:6

    Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Binding Sites; Cell Line; Drug Design; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indoles; Models, Molecular; Molecular Conformation; Nitriles; Phosphinic Acids; Pyrazoles; Pyridazines; Pyridines; Pyrimidines; Quinoxalines; Reverse Transcriptase Inhibitors; Rilpivirine

2010
[Discovery and development of diarylpyrimidines (DAPYs) as next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs)].
    Yao xue xue bao = Acta pharmaceutica Sinica, 2010, Volume: 45, Issue:2

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Molecular Structure; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2010
Role of non-nucleoside reverse transcriptase inhibitors in treating HIV-infected children.
    Drugs, 2011, Nov-12, Volume: 71, Issue:16

    Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2011
New therapeutic landscape of NNRTIs for treatment of HIV: a look at recent data.
    Expert opinion on pharmacotherapy, 2012, Volume: 13, Issue:18

    Topics: Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Drug Resistance, Viral; HIV; HIV Infections; Humans; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2012
Hepatoxicity of new antiretrovirals: a systematic review.
    Clinics and research in hepatology and gastroenterology, 2013, Volume: 37, Issue:2

    Topics: Anti-Retroviral Agents; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cyclohexanes; Darunavir; Heterocyclic Compounds, 3-Ring; Humans; Maraviroc; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Rilpivirine; Sulfonamides; Triazoles

2013

Trials

3 trial(s) available for etravirine and rilpivirine

ArticleYear
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Antiviral therapy, 2011, Volume: 16, Issue:7

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine

2011
Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
    The Journal of antimicrobial chemotherapy, 2015, Volume: 70, Issue:2

    Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Retreatment; Reverse Transcriptase Inhibitors; Rilpivirine; Young Adult

2015
Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
    Journal of clinical pharmacology, 2014, Volume: 54, Issue:5

    Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Drug Interactions; Female; Healthy Volunteers; Humans; Male; Middle Aged; Nitriles; Oligopeptides; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Young Adult

2014

Other Studies

59 other study(ies) available for etravirine and rilpivirine

ArticleYear
Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability.
    Journal of medicinal chemistry, 2005, Mar-24, Volume: 48, Issue:6

    Topics: Absorption; Administration, Oral; Animals; Biological Availability; Chemical Phenomena; Chemistry, Physical; Gastrointestinal Tract; Half-Life; Humans; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Light; Microscopy, Electron, Transmission; Models, Biological; Pyrimidines; Rats; Reverse Transcriptase Inhibitors; Scattering, Radiation; Solutions; Triazines

2005
Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Bioorganic & medicinal chemistry letters, 2009, Sep-15, Volume: 19, Issue:18

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Pyridines; Structure-Activity Relationship

2009
Addressing the malaria drug resistance challenge using flow cytometry to discover new antimalarials.
    Bioorganic & medicinal chemistry letters, 2009, Sep-15, Volume: 19, Issue:18

    Topics: Animals; Antimalarials; DNA, Protozoan; Drug Discovery; Drug Resistance; Erythrocytes; Flow Cytometry; Malaria, Falciparum; Parasitic Sensitivity Tests; Plasmodium falciparum; RNA, Protozoan; Structure-Activity Relationship

2009
TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1.
    Antimicrobial agents and chemotherapy, 2010, Volume: 54, Issue:2

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cell Line; Cells, Cultured; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Molecular Structure; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine

2010
Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents.
    Journal of medicinal chemistry, 2011, Dec-22, Volume: 54, Issue:24

    Topics: Anti-HIV Agents; Catechols; Computer Simulation; Ethers; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Protein Binding; Quantitative Structure-Activity Relationship; Reverse Transcriptase Inhibitors; Stereoisomerism; T-Lymphocytes

2011
Strategies for the design of HIV-1 non-nucleoside reverse transcriptase inhibitors: lessons from the development of seven representative paradigms.
    Journal of medicinal chemistry, 2012, Apr-26, Volume: 55, Issue:8

    Topics: Anti-HIV Agents; Benzodiazepines; Binding Sites; Crystallography, X-Ray; Drug Design; HIV Reverse Transcriptase; HIV-1; Hydrogen Bonding; Imidazoles; Indoles; Nitriles; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2012
Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
    Journal of medicinal chemistry, 2012, Aug-23, Volume: 55, Issue:16

    Topics: Aniline Compounds; Anti-HIV Agents; Cell Line; Drug Design; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Microsomes, Liver; Mutation; Reverse Transcriptase Inhibitors; Solubility; Stereoisomerism; Structure-Activity Relationship; Virus Replication

2012
Rational design of potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Journal of medicinal chemistry, 2012, Dec-13, Volume: 55, Issue:23

    Topics: Crystallography, X-Ray; Drug Design; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Reverse Transcriptase Inhibitors

2012
Optimization of benzyloxazoles as non-nucleoside inhibitors of HIV-1 reverse transcriptase to enhance Y181C potency.
    Bioorganic & medicinal chemistry letters, 2013, Feb-15, Volume: 23, Issue:4

    Topics: Anti-HIV Agents; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Molecular design, synthesis and biological evaluation of BP-O-DAPY and O-DAPY derivatives as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    European journal of medicinal chemistry, 2013, Volume: 65

    Topics: Anti-HIV Agents; Benzophenones; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2013
Optimization of diarylazines as anti-HIV agents with dramatically enhanced solubility.
    Bioorganic & medicinal chemistry letters, 2013, Sep-15, Volume: 23, Issue:18

    Topics: Anti-HIV Agents; Cell Line, Transformed; Cell Proliferation; Dose-Response Relationship, Drug; HIV-1; Humans; Hydrazines; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Solubility; Structure-Activity Relationship

2013
Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
    Bioorganic & medicinal chemistry letters, 2014, Feb-01, Volume: 24, Issue:3

    Topics: Animals; Anti-HIV Agents; Cells, Cultured; Crystallography, X-Ray; Dogs; Drug Discovery; Drug Resistance, Viral; HIV-1; Humans; Inhibitory Concentration 50; Molecular Structure; Mutation; Pyridones; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Triazoles

2014
Discovery of 2-pyridone derivatives as potent HIV-1 NNRTIs using molecular hybridization based on crystallographic overlays.
    Bioorganic & medicinal chemistry, 2014, Mar-15, Volume: 22, Issue:6

    Topics: Anti-HIV Agents; Crystallization; Dose-Response Relationship, Drug; Drug Discovery; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Pyridones; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2014
Picomolar Inhibitors of HIV-1 Reverse Transcriptase: Design and Crystallography of Naphthyl Phenyl Ethers.
    ACS medicinal chemistry letters, 2014, Nov-13, Volume: 5, Issue:11

    Topics:

2014
Discovery and Structure-Based Optimization of 2-Ureidothiophene-3-carboxylic Acids as Dual Bacterial RNA Polymerase and Viral Reverse Transcriptase Inhibitors.
    Journal of medicinal chemistry, 2016, Aug-11, Volume: 59, Issue:15

    Topics: Anti-Bacterial Agents; Anti-HIV Agents; Carboxylic Acids; DNA-Directed RNA Polymerases; Dose-Response Relationship, Drug; Drug Discovery; Enzyme Inhibitors; Escherichia coli; HEK293 Cells; HeLa Cells; HIV; Humans; Microbial Sensitivity Tests; Molecular Structure; RNA-Directed DNA Polymerase; Structure-Activity Relationship; Thiophenes

2016
Computer-aided discovery of anti-HIV agents.
    Bioorganic & medicinal chemistry, 2016, 10-15, Volume: 24, Issue:20

    Topics: Anti-HIV Agents; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; T-Lymphocytes

2016
Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
    Bioorganic & medicinal chemistry letters, 2017, 06-15, Volume: 27, Issue:12

    Topics: Aniline Compounds; Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Microbial Sensitivity Tests; Molecular Structure; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine; Structure-Activity Relationship; Virus Replication

2017
Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    European journal of medicinal chemistry, 2018, May-10, Volume: 151

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Molecular Docking Simulation; Niacinamide; Point Mutation; Structure-Activity Relationship; Triazoles

2018
The Journey of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) from Lab to Clinic.
    Journal of medicinal chemistry, 2019, 05-23, Volume: 62, Issue:10

    Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Discovery; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors

2019
Molecular and cellular studies evaluating a potent 2-cyanoindolizine catechol diether NNRTI targeting wildtype and Y181C mutant HIV-1 reverse transcriptase.
    Bioorganic & medicinal chemistry letters, 2019, 08-15, Volume: 29, Issue:16

    Topics: Anti-HIV Agents; Catechols; Drug Design; HIV Reverse Transcriptase; Molecular Structure; Reverse Transcriptase Inhibitors

2019
Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel.
    Journal of medicinal chemistry, 2020, 02-13, Volume: 63, Issue:3

    Topics: Animals; Anti-HIV Agents; Cell Line; Crystallography, X-Ray; Drug Discovery; ERG1 Potassium Channel; Female; Fluorine; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Microsomes, Liver; Molecular Structure; Protein Binding; Pyrimidines; Rats, Wistar; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Thiophenes

2020
Novel indolylarylsulfone derivatives as covalent HIV-1 reverse transcriptase inhibitors specifically targeting the drug-resistant mutant Y181C.
    Bioorganic & medicinal chemistry, 2021, 01-15, Volume: 30

    Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Resistance, Viral; HIV Reverse Transcriptase; HIV-1; Indoles; Molecular Structure; Mutation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Sulfones

2021
2,4,5-Trisubstituted Pyrimidines as Potent HIV-1 NNRTIs: Rational Design, Synthesis, Activity Evaluation, and Crystallographic Studies.
    Journal of medicinal chemistry, 2021, 04-08, Volume: 64, Issue:7

    Topics: Animals; Anti-HIV Agents; Crystallography, X-Ray; Drug Design; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Microbial Sensitivity Tests; Molecular Structure; Mutation; Protein Binding; Pyrimidines; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from
    Journal of medicinal chemistry, 2021, 04-22, Volume: 64, Issue:8

    Topics: Alkylation; Animals; Binding Sites; Biphenyl Compounds; Cell Line; Cell Survival; Drug Design; Drug Stability; Female; Half-Life; HIV Reverse Transcriptase; Humans; Hydrophobic and Hydrophilic Interactions; Mice; Microsomes, Liver; Molecular Docking Simulation; Mutation; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Improving Druggability of Novel Diarylpyrimidine NNRTIs by a Fragment-Based Replacement Strategy: From Biphenyl-DAPYs to Heteroaromatic-Biphenyl-DAPYs.
    Journal of medicinal chemistry, 2021, 07-22, Volume: 64, Issue:14

    Topics: Animals; Anti-HIV Agents; Dose-Response Relationship, Drug; Female; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Models, Molecular; Molecular Structure; Pyrimidines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies.
    Journal of medicinal chemistry, 2021, 09-23, Volume: 64, Issue:18

    Topics: Anti-HIV Agents; Cell Line; Drug Design; Heterocyclic Compounds, 2-Ring; HIV Reverse Transcriptase; HIV-1; Humans; Microsomes, Liver; Molecular Dynamics Simulation; Molecular Structure; Mutation; Protein Binding; Pyridines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2021
Discovery of Novel Pyridine-Dimethyl-Phenyl-DAPY Hybrids by Molecular Fusing of Methyl-Pyrimidine-DAPYs and Difluoro-Pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK.
    Journal of medicinal chemistry, 2022, 02-10, Volume: 65, Issue:3

    Topics: Animals; Anti-HIV Agents; Binding Sites; Cell Survival; Cytochrome P-450 Enzyme System; Drug Design; Drug Resistance, Viral; Drug Stability; Female; Half-Life; HIV Reverse Transcriptase; HIV-1; Humans; Mice; Molecular Docking Simulation; Mutation; Pyridines; Pyrimidines; Solubility; Structure-Activity Relationship

2022
Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors.
    Journal of medicinal chemistry, 2022, 03-10, Volume: 65, Issue:5

    Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Heterocyclic Compounds, 1-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors

2022
Structure-Based Discovery of Novel NH
    Journal of medicinal chemistry, 2022, 06-23, Volume: 65, Issue:12

    Topics: Anti-HIV Agents; Biphenyl Compounds; Drug Design; Heterocyclic Compounds, 1-Ring; HIV Reverse Transcriptase; HIV-1; Pyrimidines; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2022
Expansion of the S-CN-DABO scaffold to exploit the impact on inhibitory activities against the non-nucleoside HIV-1 reverse transcriptase.
    European journal of medicinal chemistry, 2022, Aug-05, Volume: 238

    Topics: Animals; Anti-HIV Agents; HIV Reverse Transcriptase; HIV-1; Mice; Molecular Docking Simulation; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Structure-Activity Relationship

2022
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
Drug interactions with new and investigational antiretrovirals.
    Clinical pharmacokinetics, 2010, Volume: 49, Issue:1

    Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Drug Interactions; Humans; Nitriles; Pyridazines; Pyrimidines; Rilpivirine

2010
Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds.
    Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2010, Jun-01, Volume: 878, Issue:19

    Topics: Analysis of Variance; Anti-HIV Agents; Chromatography, High Pressure Liquid; Cyclohexanes; Drug Stability; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Reproducibility of Results; Rilpivirine; Sensitivity and Specificity; Tandem Mass Spectrometry; Triazoles

2010
Crystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug design.
    Journal of medicinal chemistry, 2010, May-27, Volume: 53, Issue:10

    Topics: Binding Sites; Crystallography, X-Ray; Drug Design; HIV Reverse Transcriptase; HIV-1; Models, Molecular; Mutation; Nitriles; Protein Binding; Protein Conformation; Pyridazines; Pyrimidines; Rilpivirine

2010
Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.
    Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:8

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cloning, Molecular; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2012
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.
    AIDS (London, England), 2012, Aug-24, Volume: 26, Issue:13

    Topics: Adenine; Anti-HIV Agents; APOBEC Deaminases; Cytidine Deaminase; Cytosine Deaminase; DNA Mutational Analysis; Drug Resistance, Viral; Female; Glutamic Acid; HIV Reverse Transcriptase; HIV-1; Humans; Isoleucine; Lysine; Male; Methionine; Mutation; Nitriles; Organophosphonates; Pyridazines; Pyrimidines; Rilpivirine; Tenofovir; Treatment Failure; Virus Replication

2012
[HIV therapy of the next generation. Modern active drugs for long-term treatment].
    MMW Fortschritte der Medizin, 2012, May-16, Volume: 154 Suppl 1

    Topics: Anti-HIV Agents; Clinical Trials as Topic; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; Humans; Long-Term Care; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sulfonamides

2012
Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline.
    AIDS (London, England), 2013, Mar-27, Volume: 27, Issue:6

    Topics: Anti-HIV Agents; DNA Mutational Analysis; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Selection, Genetic; Serial Passage; Virus Replication

2013
Agonism of human pregnane X receptor by rilpivirine and etravirine: comparison with first generation non-nucleoside reverse transcriptase inhibitors.
    Biochemical pharmacology, 2013, Jun-01, Volume: 85, Issue:11

    Topics: Cell Line, Tumor; Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Genes, Reporter; Humans; Hydroxylation; Nitriles; Pregnane X Receptor; Pyridazines; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptors, Steroid; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Rilpivirine; Steroid Hydroxylases; Two-Hybrid System Techniques

2013
Effect of mutations at position E138 in HIV-1 reverse transcriptase and their interactions with the M184I mutation on defining patterns of resistance to nonnucleoside reverse transcriptase inhibitors rilpivirine and etravirine.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:7

    Topics: Anti-HIV Agents; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication

2013
Genetic barrier to the development of resistance to rilpivirine and etravirine between HIV-1 subtypes CRF02_AG and B.
    The Journal of antimicrobial chemotherapy, 2013, Volume: 68, Issue:11

    Topics: Anti-HIV Agents; Conserved Sequence; Drug Resistance, Viral; Genotype; HIV-1; Humans; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Rilpivirine

2013
Role of the K101E substitution in HIV-1 reverse transcriptase in resistance to rilpivirine and other nonnucleoside reverse transcriptase inhibitors.
    Antimicrobial agents and chemotherapy, 2013, Volume: 57, Issue:11

    Topics: Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Delavirdine; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Reverse Transcriptase; HIV-1; Humans; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Mutagenesis, Site-Directed; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication

2013
The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.
    Journal of virology, 2014, Volume: 88, Issue:3

    Topics: Amino Acid Motifs; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication

2014
Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine.
    Antiviral therapy, 2014, Volume: 19, Issue:8

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Microbial Sensitivity Tests; Mutation; Nitriles; Prevalence; Pyridazines; Pyrimidines; Rilpivirine; United States

2014
Etravirine and rilpivirine-specific mutations selected by efavirenz and nevirapine exposure in patients infected with HIV-1 non-B subtypes.
    AIDS (London, England), 2014, Sep-24, Volume: 28, Issue:15

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Mutation, Missense; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Treatment Outcome; Viral Load

2014
Differential activation of human constitutive androstane receptor and its SV23 and SV24 splice variants by rilpivirine and etravirine.
    British journal of pharmacology, 2015, Volume: 172, Issue:5

    Topics: Adolescent; Adult; Aged; Alternative Splicing; Constitutive Androstane Receptor; Cytochrome P-450 CYP2B6; Dose-Response Relationship, Drug; Female; Hep G2 Cells; Hepatocytes; Humans; Male; Molecular Structure; Nitriles; Pyridazines; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Inhibitors; Rilpivirine; Structure-Activity Relationship; Tumor Cells, Cultured; Young Adult

2015
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
    Antimicrobial agents and chemotherapy, 2015, Volume: 59, Issue:1

    Topics: Anti-HIV Agents; Drug Resistance, Viral; HEK293 Cells; HIV-1; Humans; Mutation; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Selection, Genetic; Triazoles

2015
Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis.
    Nucleic acids research, 2015, Feb-27, Volume: 43, Issue:4

    Topics: Anti-HIV Agents; DNA; Drug Resistance, Viral; HIV Reverse Transcriptase; Mutation; Nitriles; Protein Structure, Tertiary; Purines; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Ribonuclease H; Rilpivirine; RNA; Templates, Genetic

2015
Mass Spectrometric Characterization of HIV-1 Reverse Transcriptase Interactions with Non-nucleoside Reverse Transcriptase Inhibitors.
    Biological & pharmaceutical bulletin, 2016, Volume: 39, Issue:3

    Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Reverse Transcriptase; Mass Spectrometry; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2016
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
    PloS one, 2016, Volume: 11, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Thailand; Viral Load; Young Adult

2016
Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
    Journal of pharmaceutical and biomedical analysis, 2016, Nov-30, Volume: 131

    Topics: Chromatography, Liquid; Cyclohexanes; Humans; Maraviroc; Nitriles; Pyridazines; Pyrimidines; Raltegravir Potassium; Reproducibility of Results; Rilpivirine; Tandem Mass Spectrometry; Triazoles

2016
Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.
    AIDS research and human retroviruses, 2017, Volume: 33, Issue:6

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Male; Mutation, Missense; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Rilpivirine; Sequence Analysis, DNA; Treatment Failure

2017
Prevalence of Rilpivirine and Etravirine Resistance Mutations in HIV-1 Subtype C-Infected Patients Failing Nevirapine or Efavirenz-Based Combination Antiretroviral Therapy in Botswana.
    AIDS research and human retroviruses, 2018, Volume: 34, Issue:8

    Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Botswana; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; Genotyping Techniques; HIV Infections; HIV-1; Humans; Male; Microbial Sensitivity Tests; Mutation; Nevirapine; Nitriles; pol Gene Products, Human Immunodeficiency Virus; Prevalence; Pyridazines; Pyrimidines; Rilpivirine; Treatment Failure; Young Adult

2018
Dynamics of drug resistance-associated mutations in HIV-1 DNA reverse transcriptase sequence during effective ART.
    The Journal of antimicrobial chemotherapy, 2018, 08-01, Volume: 73, Issue:8

    Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Evolution, Molecular; Female; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; RNA, Viral

2018
Frequency of cross-resistance to rilpivirine and etravirine among HIV-1 subtype C infected individuals failing nevirapine/efavirenz based ART regimen.
    Infectious diseases (London, England), 2019, Volume: 51, Issue:1

    Topics: Alkynes; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Rilpivirine; Sweden

2019
Prevalence of predicted resistance to doravirine in HIV-1-positive patients after exposure to non-nucleoside reverse transcriptase inhibitors.
    International journal of antimicrobial agents, 2019, Volume: 53, Issue:4

    Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Delavirdine; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Male; Nevirapine; Nitriles; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome; Triazoles

2019
Trends in HIV-1 Drug Resistance Mutations from a U.S. Reference Laboratory from 2006 to 2017.
    AIDS research and human retroviruses, 2019, Volume: 35, Issue:8

    Topics: Anti-HIV Agents; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Nitriles; Oxazines; Piperazines; Pyridazines; Pyridones; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine

2019
Design and Synthesis of Novel HIV-1 NNRTIs with Bicyclic Cores and with Improved Physicochemical Properties.
    Journal of medicinal chemistry, 2023, 02-09, Volume: 66, Issue:3

    Topics: Anti-HIV Agents; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Reverse Transcriptase Inhibitors; Rilpivirine

2023
Residual phenotypic susceptibility to doravirine in multidrug-resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry.
    International journal of antimicrobial agents, 2023, Volume: 61, Issue:3

    Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine

2023